Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | +0.51% | +0.01% | -37.38% |
Mar. 28 | Arcadia Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 28 | Transcript : Arcadia Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Financials (USD)
Sales 2024 * | 6.22M | Sales 2025 * | 8M | Capitalization | 2.66M |
---|---|---|---|---|---|
Net income 2024 * | -10M | Net income 2025 * | -8M | EV / Sales 2024 * | 0.43 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.33 x |
P/E ratio 2024 * |
-0.35
x | P/E ratio 2025 * |
-0.42
x | Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.4% |
Latest transcript on Arcadia Biosciences, Inc.
1 day | -3.93% | ||
1 week | -1.25% | ||
Current month | -11.76% | ||
1 month | -21.05% | ||
3 months | -25.85% | ||
6 months | -41.08% | ||
Current year | -37.70% |
Managers | Title | Age | Since |
---|---|---|---|
Stanley Jacot
CEO | Chief Executive Officer | 54 | 22-02-01 |
Thomas Schaefer
DFI | Director of Finance/CFO | 48 | 20-06-30 |
Kevin Comcowich
CHM | Chairman | 55 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Amy Yoder
BRD | Director/Board Member | 56 | 17-08-09 |
Gregory Waller
BRD | Director/Board Member | 74 | 17-06-12 |
Kevin Comcowich
CHM | Chairman | 55 | 16-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.96 | +0.51% | 12 319 |
24-04-18 | 1.95 | -3.93% | 17,324 |
24-04-17 | 2.03 | +5.72% | 67,079 |
24-04-16 | 1.92 | +1.59% | 16,070 |
24-04-15 | 1.89 | -3.57% | 6,366 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.70% | 2.66M | |
+12.60% | 37.71B | |
-.--% | 10.93B | |
-9.69% | 7.11B | |
+5.61% | 6.74B | |
-2.75% | 6.01B | |
-6.21% | 5.6B | |
+33.46% | 5.28B | |
-20.36% | 5.05B | |
+21.61% | 4.54B |
- Stock Market
- Equities
- RKDA Stock